The increased capacity of the new manufacturing facility, together with advances in ZFN design algorithms and production processes, has led to cost reductions in the development and production for both CompoZr Custom and Knockout ZFNs.
This milestone in genome editing is expected to enable the scientific community to pursue previously unachievable research quickly and easily with validated tools, avoiding the cost, time and uncertainty associated with other techniques.
Sigma chief scientific officer David Smoller said CompoZr ZFNs are now available in multiple formats, multiple species and at more accessible pricing.
"It is now our objective to continue to drive the development of new applications for CompoZr ZFNs while maintaining this vital affordability," Smoller said.